Education
About Us
Working with TipRanks
Follow Us
Galectin Therapeutics Inc (GALT)
NASDAQ:GALT
GALT Stock Chart & Stats
$5.11
-$0.06(-5.00%)
At close: 4:00 PM EST
$5.11
-$0.06(-5.00%)
Day’s Range― - ―
52-Week Range$0.73 - $6.55
Previous CloseN/A
Volume135.57K
Average Volume (3M)341.94K
Market Cap
$327.35M
Enterprise Value$242.83M
Total Cash (Recent Filing)$13.77M
Total Debt (Recent Filing)$120.51M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Nov 17, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding64,060,265
10 Day Avg. Volume287,288
30 Day Avg. Volume341,945
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue6.75K
Enterprise Value/Gross Profit-80.94K
Enterprise Value/Ebitda-7.24
Forecast
1Y Price Target
$6.00Price Target Upside17.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical PotentialBelapectin 2 mg/kg exhibited a significant positive effect on reducing hepatic venous pressure gradient in patients with MASH cirrhosis without varices at baseline.
Regulatory And Partnership OpportunitiesGalectin's lead asset, belapectin, is currently in development to treat MASH-associated liver cirrhosis and portal hypertension, with ongoing regulatory engagement and potential partnership opportunities.
Unique Treatment OfferingBelapectin is the only therapy in development for MASH cirrhosis and portal hypertension, addressing a patient population with no approved therapies.
Bears Say
Challenges In Clinical TrialsBelapectin's clinical journey has been bumpy, with neither dose achieving the primary endpoint in early trials.
Statistical SignificanceThe composite endpoint in the NAVIGATE trial did not reach statistical significance in the intent-to-treat population.
Galectin Therapeutics News
GALT FAQ
What was Galectin Therapeutics Inc’s price range in the past 12 months?
Galectin Therapeutics Inc lowest stock price was $0.73 and its highest was $6.55 in the past 12 months.
What is Galectin Therapeutics Inc’s market cap?
Galectin Therapeutics Inc’s market cap is $327.35M.
When is Galectin Therapeutics Inc’s upcoming earnings report date?
Galectin Therapeutics Inc’s upcoming earnings report date is Nov 17, 2025 which is in 18 days.
How were Galectin Therapeutics Inc’s earnings last quarter?
Galectin Therapeutics Inc released its earnings results on Aug 14, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.04.
Is Galectin Therapeutics Inc overvalued?
According to Wall Street analysts Galectin Therapeutics Inc’s price is currently Undervalued.
Does Galectin Therapeutics Inc pay dividends?
Galectin Therapeutics Inc does not currently pay dividends.
What is Galectin Therapeutics Inc’s EPS estimate?
Galectin Therapeutics Inc’s EPS estimate is -0.11.
How many shares outstanding does Galectin Therapeutics Inc have?
Galectin Therapeutics Inc has 64,060,265 shares outstanding.
What happened to Galectin Therapeutics Inc’s price movement after its last earnings report?
Galectin Therapeutics Inc reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went up 2.452%.
Which hedge fund is a major shareholder of Galectin Therapeutics Inc?
Currently, no hedge funds are holding shares in GALT
Galectin Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (17.42% Upside)
$6.00 (17.42% Upside)
Insider Transactions
Sold Shares
Worth $246.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-43.58%
Trailing 12-Months
Company Description
Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
GALT Stock 12 Month Forecast
Average Price Target
$6.00
▲(17.42% Upside)
Technical Analysis
Omeros
―
Voyager Therapeutics
―
Tectonic Therapeutic
―
Jade Biosciences
―
Tenaya Therapeutics
―
Ownership Overview
19.65% Insiders
4.24% Mutual Funds
<0.01% Other Institutional Investors
72.83% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---